use of "vinorelbine" in the Treatment of advanced non-small Cell lung cancer

ABSTRACT

This study included 19 patients suffering from advanced non-small cell lung cancer [NSCLC]. They were treated either with Vinorelbine-Cisplatinum; or Vinorelbine as a single agent for elderly patients, or those with poor performance status, or with renal impairment [9 cases]. Objective partial response was achieved in 5 cases [26%] with median duration of response for 25 weeks for the whole study group. The response was comparable in both treatment arms; with better tolerance in patients receiving Vinorelbine alone. This study demonstrates the efficiency of Vinorelbine in the treatment of advanced NSCLC either in combination with Cisplatinum, or as a single agent in elderly frail patients